Abstract: A pharmaceutically acceptable composition comprising an effective amount of a dasatinib or a pharmaceutically acceptable salt thereof, and a binder, one or more diluent or mixture thereof, a disintegrant, a lubricant, wherein said composition is devoid of dasatinib hydrate or solvate or any crystalline polymorph, wherein the dasatinib or a pharmaceutically acceptable salt thereof, is present in an amorphous form.

Abstract: The present invention refers to an improved pharmaceutical composition of diclofenac or pharmaceutically acceptable salt and pharmaceutically acceptable excipients wherein the composition is substantially free of dispersing agents. By judicially using pharmaceutical excipients other than dispersing agent, pharmaceutical composition of diclofenac or its salts with rapid and uniform gastrointestinal absorption of diclofenac can be achieved. The composition of the invention can also minimize the controllable side effects of diclofenac.

Abstract: The present invention refers to an improved pharmaceutical composition of diclofenac or pharmaceutically acceptable salt comprising dispersing agent and pharmaceutically acceptable excipients. The invention relates to pharmaceutical composition of diclofenac or pharmaceutically acceptable salt and lower amount of dispersing agents. By administering such composition, rapid and uniform gastrointestinal absorption of diclofenac can be achieved. The invention also includes process of preparing such composition.

Abstract: The present invention refers to an improved pharmaceutical composition of diclofenac or pharmaceutically acceptable salt and pharmaceutically acceptable excipients wherein the composition is substantially free of solubilizing agents. By judicially using pharmaceutical excipients other than solubilizing agent, pharmaceutical composition of diclofenac or its salts with rapid and uniform gastrointestinal absorption of diclofenac can be achieved. The composition of the invention can also minimize the controllable side effects of diclofenac.

Abstract: There is provided a modified release dosage form comprising a core coated with a polymeric coat, said polymeric coat comprising one or more rate controlling polymers, said dosage form having a hole extending through the dosage form resulting in an inner radial surface and an outer radial surface, said core comprising at least one therapeutically active ingredient, characterized in that the inner radial surface is partially coated with said polymeric coat.

Abstract: This invention is related to a device for the manufacture of a dosage form with a hole and method of manufacture. The dosage form may be a modified release dosage form comprising a core coated with a polymeric coat comprising one or more rate controlling polymers, said dosage form having a hole extending through the dosage form resulting in an inner radial surface and an outer radial surface, said core comprising at least one therapeutically active ingredient, characterized in that the inner radial surface is partially coated with said polymeric coat.

Abstract: The present invention provides a pharmaceutical composition comprising adsorbate of fenofibrate or salt thereof or fenofibrate adsorbed on a pharmaceutically acceptable adsorbent and optionally one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such compositions.